Viridian Therapeutics: Wells Fargo raises target price to $39 from $34
VRDN•Wells Fargo raised its target price for Viridian Therapeutics to $39 from $34.
Related News
Urban One Q3 revenue falls, net loss widens on weak radio and digital demand
UONEK•
Realty Income target price raised to $63 from $60
O•
Oil's peace trade risks a rude awakening
USO•
Ferguson Enterprises: Deutsche Bank raises target price to $273 from $235
FERG•
Manchester United sets fiscal 2027 first-quarter results release
MANU•